Top 5 Drug Type | Count |
---|---|
Small molecule drug | 2 |
Top 5 Target | Count |
---|---|
DAT x SERT x κ opioid receptor x μ opioid receptor | 1 |
Mechanism DAT agonists [+3] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Ibogaine ( DAT x SERT x κ opioid receptor x μ opioid receptor ) | Mood Disorders More | Preclinical |
MC-808 | Behavioural disorders More | Preclinical |
MC-106 | Behavioural disorders More | Discontinued |